EBR Systems (ASX:EBR) is targeting an around $3.6 billion initial addressable market at the commercial launch of its Wireless Stimulation Endocardially (WiSE) Cardiac Resynchronisation Therapy (CRT) system, according to a Thursday Australian bourse filing.
The firm submitted its application to the US Centers for Medicare & Medicaid Services for the transitional pass-through reimbursement scheme for its proprietary WiSE CRT system.
The biggest segment in the initial addressable market is expected to be patients for whom the traditional CRT system implant has ceased to provide effective CRT. This segment represents $1.45 billion.
High-risk patients and patients with a leadless right ventricle pacemaker are also part of the firm's initial addressable market. Medtronic's Micra leadless pacemaker has been qualified for use with the WiSE CRT system.
The firm's shares slumped 12% in recent trading on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。